EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Cilostazol Plus P2Y12 Inhibitor Compared to Aspirin Plus P2Y12 Inhibitor in the Reduction of Adverse Cardiovascular Events and Bleeding in Patients who have Undergone Coronary Angioplasty with Stenting

Rossel Anjelo A Ambal, Joyce Angeli P Estrellado, Al Christopher O.S Ramos, Jaime Alfonso M Aherrera

Philippine Journal of Cardiology · 20.06.2026 · 54 (1) · 84-89

DOI: 10.69944/pjc.0bc16d2f0b ↗

Kurz gefasst

Fachartikel in der Zeitschrift Philippine Journal of Cardiology, online erschienen am 20.06.2026. Verfasst von Rossel Anjelo A Ambal und 3 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dual antiplatelet therapy (DAPT) with aspirin plus P2Y12 receptor inhibitor has become a cornerstone in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) for the prevention of stent thrombosis. However, aspirin intolerance poses a problem in the lack of guideline-based alternatives with proven benefit. In this study, we aim to determine the efficacy and safety of cilostazol-based DAPT as an alternative treatment for aspirin among patients undergoing PCI.

Methods

A comprehensive literature search was performed. All studies that investigated cilostazol as an alternative to aspirin on top of P2Y12 inhibitors for patients undergoing PCI were included. Outcomes of interest in this meta-analysis were reduction of major adverse cardiovascular events (MACE) and bleeding.

Results

Three cohort studies including 1,227 patients on cilostazol and 1,480 on aspirin, both with a P2Y12 inhibitor were analyzed. Pooled estimates showed no significant difference in MACE (OR 1.32, 95% CI 0.79–2.23; p = 0.29) or acute myocardial infarction (OR 0.94, 95% CI 0.46–1.89; p = 0.85) between groups. However, cilostazol-based DAPT was associated with significantly less bleeding (OR 0.52, 95% CI 0.27–0.99; p = 0.05). All outcomes were statistically homogeneous (p>0.1, I²

Zitieren

APA

Ambal, R. A. A., Estrellado, J. A. P., Ramos, A. C. O., & Aherrera, J. A. M. (2026). Efficacy and Safety of Cilostazol Plus P2Y12 Inhibitor Compared to Aspirin Plus P2Y12 Inhibitor in the Reduction of Adverse Cardiovascular Events and Bleeding in Patients who have Undergone Coronary Angioplasty with Stenting. Philippine Journal of Cardiology, 54(1), 84-89. https://doi.org/10.69944/pjc.0bc16d2f0b

Vancouver

Ambal RAA, Estrellado JAP, Ramos ACO, Aherrera JAM. Efficacy and Safety of Cilostazol Plus P2Y12 Inhibitor Compared to Aspirin Plus P2Y12 Inhibitor in the Reduction of Adverse Cardiovascular Events and Bleeding in Patients who have Undergone Coronary Angioplasty with Stenting. Philippine Journal of Cardiology. 2026;54(1):84-89. doi:10.69944/pjc.0bc16d2f0b

BibTeX
@article{Ambal2026,
  author = {Ambal, Rossel Anjelo A and Estrellado, Joyce Angeli P and Ramos, Al Christopher O.S and Aherrera, Jaime Alfonso M},
  title = {Efficacy and Safety of Cilostazol Plus P2Y12 Inhibitor Compared to Aspirin Plus P2Y12 Inhibitor in the Reduction of Adverse Cardiovascular Events and Bleeding in Patients who have Undergone Coronary Angioplasty with Stenting},
  journal = {Philippine Journal of Cardiology},
  year = {2026},
  volume = {54},
  number = {1},
  pages = {84--89},
  doi = {10.69944/pjc.0bc16d2f0b}
}
Kostenlos starten →